UNICREDIT BANK/CALL/ELI LILLY & CO/1150/0.1/17.06.26 | Market Closed - BOERSE MUENCHEN 03:41:37 2024-05-24 pm EDT | ||
| 7.31 EUR | -0.81% |
|
| Current month | +10.26% | ||
| 1 month | +36.38% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 7.31 | -0.81% |
| 24-05-23 | 7.37 | +5.29% |
| 24-05-22 | 7 | -0.14% |
| 24-05-21 | 7.01 | +12.88% |
| 24-05-20 | 6.21 | +4.37% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4LBP |
| ISIN | DE000HD4LBP2 |
| Date issued | 2024-04-12 |
| Strike | 1,150 $ |
| Maturity | 2026-06-17 (753 Days) |
| Parity | 10 : 1 |
| Emission price | 6.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.37 € |
|---|---|
| Lowest since issue | 5.07 € |
| Spread | 0.13 € |
| Spread % | 1.78% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- Warrant
